Intellia Therapeutics Stock News

Eight months after delivering promising biomarker data from one of the first CRISPR trials, Intellia Therapeutics Inc (NASDAQ: NTLA ) presented additional data from the Phase 1 trial for NTLA-2001 in transthyretin, or ATTR, amyloidosis. In the initial study, Intellia showed that a single infusion of its gene-editing therapy could lower the amount of toxic protein in six … Full story available on Benzinga.com

Intellia successfully lowered a problematic protein in patients with a liver disease on Monday, but NTLA stock fell on a patent decision.

On Monday, Intellia Therapeutics (NTLA) and Regeneron Pharmaceuticals (REGN) issued updated interim data for CRISPR gene editing candidate NTLA-2001 from a Phase 1 trial in…

The one-time therapy is also showing a sustained effect, with protein reductions remaining stable in previously treated patients.

CAMBRIDGE, Mass. and TARRYTOWN, N.Y. , Feb. 28, 2022 /PRNewswire/ -- Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with patient

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim d

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The interim data released today include 15 hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients treated across four single-ascending dose cohorts. Single doses of 0.1 mg/kg, 0.3 mg/kg, 0.7 mg/kg, and 1.0 mg/kg of NTLA-2001 were administered via intravenous infusion and changes from baseline values of serum transthyretin (TTR) protein were measured for each patient. Treatment with NTLA-2001 led to dose-dependent reductions in serum TTR and achieved maximal reductions by day 28, with mean reductions of 52%, 87%, and 86% among the three patients each in the 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg dose groups, respectively, and 93% among the six patients in the 1.

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Intellia Therapeutics reported its FY21 results. Intellia announced a lease agreement to build a manufacturing facility. The recent acquisition of Rewrite Therapeutics can lead to strong synergies.

Intellia Therapeutics <> Q4 collaboration revenue rose 94.91% Y/Y to $12.85M.The company said the increase was mainly driven by $5.8M in revenue recorded in 2021 from its…

Intellia Therapeutics' (NTLA) CEO John Leonard on Q4 2021 Results - Earnings Call Transcript

Intellia Therapeutics press release (NTLA): Q4 GAAP EPS of -$1.09 misses by $0.15.Revenue of $12.85M (+94.7% Y/Y) beats by $5.02M.